SEC Filing Summary: Tivic Health Systems, Inc. (TIVC)
Business Context and Reporting Period
This Form 8-K, dated March 25, 2026, is a current report filed by Tivic Health Systems, Inc. (not Valion Bio, Inc., as noted in the request metadata). The filing serves to disclose the Company's financial results for the fiscal year ended December 31, 2025, via a press release furnished as Exhibit 99.1. The Company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol TIVC.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) referenced in Item 7.01 but are not reproduced in the body of this 8-K document. Consequently, no specific financial figures can be extracted from the provided source text.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It solely references the issuance of a press release regarding the year-end 2025 results. Any material changes would be detailed in the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The document includes a standard "Forward-Looking Statements" disclaimer. It warns that statements involving terms such as "anticipates," "expects," and "believes" are subject to substantial risks and uncertainties. The filing notes that actual results may differ materially from those expressed due to known and unknown factors, including risks set forth in other SEC filings. No specific guidance or management commentary on future performance is included in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review Exhibit 99.1 (Press Release dated March 25, 2026) for actual financial figures for the year ended December 31, 2025.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting.
- Examine the referenced press release for specific details on material changes and forward-looking guidance not present in this summary.